On February 24, 2026, Palvella Therapeutics, Inc. will host a call to discuss topline results from the Phase 3 SELVA study of their QTORIN™ gel for treating lymphatic malformations. The event will be accessible online with slides provided.
AI Assistant
PALVELLA THERAPEUTICS INC
2026
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.